Navigation Links
Isis Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
Date:2/28/2012

CARLSBAD, Calif., Feb. 28, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Cowen and Company's 32nd Annual Health Care Conference on Tuesday, March 06, 2012 at 10:40 a.m. ET at the Boston Marriot Copley Place.  

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
(Date:7/30/2015)... (NYSE: RMD ) today announced results for its ... was $453.1 million, a 9 percent increase compared with ... increase on a constant currency basis).  Net income was ... 2014.  Diluted earnings per share for the quarter were ... The results for the quarter ended ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... BETHLEHEM, Pa., Oct. 20, 2011 MedClean Technologies ... leading provider of onsite technology for the treatment ... of confidential documents and related media, today announced ... environmental firm specializing in consulting, waste disposal, engineering ...
... Oct. 20, 2011 Dey Pharma L.P., a subsidiary of ... the U.S. Patent and Trademark Office (PTO) has issued Reexamination ... (Formoterol Fumarate) Inhalation Solution 20 mcg/2mL vial thereby confirming ... Pharmaceuticals, requested the PTO to re-examine these patents, which now ...
Cached Medicine Technology:MedClean Technologies Partners With Triumvirate Environmental 2MedClean Technologies Partners With Triumvirate Environmental 3Mylan's Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents 2
(Date:8/1/2015)... , ... August 01, 2015 , ... The condition where ... both men and women often causing pain and discomfort. Those who spend a lot ... problem, and Northeast Houston Vein Center is doing what it can to create awareness ...
(Date:8/1/2015)... , ... August 01, 2015 , ... Brig and Lita ... are announcing the unification of their Healthy Home mission with the HOPE Movement of ... years, the founders of both companies have agreed to join their missions of purpose ...
(Date:8/1/2015)... Atlanta, GA (PRWEB) , ... August 01, 2015 , ... ... iPhone app that is free to download on the Apple AppStore. , The ... energy levels, even mood, thus acting as a tool to view personal health and ...
(Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive ... the Appalachian Trail by stepping off Springer Mountain and heading north. Since that ... 26th Phil reached Connecticut and was greeted by friends and family. He visited CCAR ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... cancer-causing virus enables it to bypass immune systems and infect the ... that the virus persists in the host. // ... is made by the human T cell leukemia virus type 1 ... of AIDS. ,The findings indicate that HBZ enhanced the ability ...
... has developed an electronic device that alerts women whether or not ... unwanted pregnancy. // ,The Remember Device developed by Lai ... when it is time to take her pill with a choice ... or a dual alarm vibrate mode, reported online edition of BBC ...
... more than Rs 750 crore over next four years ... Hooda said today. // ,The Congress government ... the village level and concerted efforts were being made ... he said at a rally in Jasuar Kheri village ...
... over the world will meet at Mount Abu in September ... India and how preventive measures can help control its early ... Preventive Cardiology is being held from September 22 at Mount ... issues and newer technologies besides crystallizing recent trends and newer ...
Statistics released by the Scottish Executive show that around 2.9 million clean needles were dispensed for drug users, but only 1.9 million were returned thus sparking a shortage of a million needles...
... minister of Health Manto Tshabalala-Msimang said that the traditional-medicines ... budget. A workshop was conducted on traditional-medicine in Benoni ... an interim traditional-health council. // ,Her department ... the problem lies with the allocation of money. She ...
Cached Medicine News:Health News:Cancer-Causing Virus Synthesizes Protein To Help Sustain Itself In Host Cells 2Health News:Cancer-Causing Virus Synthesizes Protein To Help Sustain Itself In Host Cells 3Health News:World Cong On Preventive Cardiology In Sept 2
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 L reference mark make it ideal for low volume pipetting....
... Peroxidase stain is the gold standard ... better agreement with your technologists manual ... efficiency. ,True RBC morphology advances cell ... allows for the differentiation of various ...
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Medicine Products: